Etrolizumab
Cat. No.: IBDI-431810
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).
Product Details
| Target |
Integrin |
| Appearance |
Liquid |
| Synonyms |
rhuMAb Beta7, RG7413, PRO145223 |
| Purity |
99.32% |
Storage & Handling
| Shipping |
Shipping with dry ice. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
